• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Long-term clinical course of complex pulmonary disease patients with treatment failure.治疗失败的复杂肺部疾病患者的长期临床病程
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0105524. doi: 10.1128/aac.01055-24. Epub 2024 Oct 29.
2
Antibiotic Maintenance and Redevelopment of Nontuberculous Mycobacteria Pulmonary Disease after Treatment of Mycobacterium avium Complex Pulmonary Disease.治疗鸟分枝杆菌复合群肺病后,非结核分枝杆菌肺病的抗生素维持和再发展。
Microbiol Spectr. 2022 Aug 31;10(4):e0108822. doi: 10.1128/spectrum.01088-22. Epub 2022 Aug 11.
3
Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.反复分枝杆菌肺病的结节性支气管扩张症间断抗生素治疗。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01812-17. Print 2018 Feb.
4
Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis.美国胸科学会/传染病学会指南推荐的多药抗生素治疗支气管扩张症合并鸟分枝杆菌复合体肺病的美国医疗保险受益人的耐受性结局。
Chest. 2024 May;165(5):1058-1069. doi: 10.1016/j.chest.2023.12.006. Epub 2023 Dec 10.
5
Managing Mycobacterium avium Complex Lung Disease With a Little Help From My Friend.在朋友的帮助下治疗鸟分枝杆菌复合体肺病。
Chest. 2021 Apr;159(4):1372-1381. doi: 10.1016/j.chest.2020.10.031. Epub 2020 Oct 17.
6
Treatment of Mycobacterium avium Complex (MAC).鸟分枝杆菌复合体(MAC)的治疗。
Semin Respir Crit Care Med. 2018 Jun;39(3):351-361. doi: 10.1055/s-0038-1660472. Epub 2018 Aug 2.
7
Evaluation of Mycobacterium Avium Complex Pulmonary Disease Treatment Completion and Adherence to ATS/IDSA Guidelines.评价鸟分枝杆菌复合体肺病治疗的完成情况和对 ATS/IDSA 指南的遵从性。
Clin Infect Dis. 2023 Feb 8;76(3):e1408-e1415. doi: 10.1093/cid/ciac394.
8
Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.鸟分枝杆菌复合群肺病:HIV 阴性患者的治疗选择
J La State Med Soc. 2008 Sep-Oct;160(5):248-54; quiz 254, 293.
9
[Clinical features and treatment history of clarithromycin resistance in M. avium-intracellulare complex pulmonary disease patients].鸟分枝杆菌复合群肺病患者克拉霉素耐药的临床特征及治疗史
Nihon Kokyuki Gakkai Zasshi. 2007 Aug;45(8):587-92.
10
Long-Term Prognosis and Antimycobacterial Glycolipid Antibody as Biomarker in Mycobacterium avium-intracellulare Complex Pulmonary Disease.抗酸分枝杆菌糖脂抗体作为鸟分枝杆菌胞内复合体肺病的生物标志物与长期预后的关系。
Microbiol Spectr. 2022 Jun 29;10(3):e0053022. doi: 10.1128/spectrum.00530-22. Epub 2022 Apr 25.

引用本文的文献

1
An unusual genetic switch controls pathogenesis, antibiotic resistance and colony morphology.一种不同寻常的基因开关控制着发病机制、抗生素耐药性和菌落形态。
bioRxiv. 2025 Jul 28:2025.07.28.667291. doi: 10.1101/2025.07.28.667291.
2
The efficacy of a regimen comprising clarithromycin, clofazimine, and bedaquiline in a mouse model of chronic lung infection.由克拉霉素、氯法齐明和贝达喹啉组成的方案在慢性肺部感染小鼠模型中的疗效。
Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0185324. doi: 10.1128/aac.01853-24. Epub 2025 Mar 14.
3
Regimen comprising clarithromycin, clofazimine and bedaquiline is more efficacious than monotherapy in a mouse model of chronic lung infection.在慢性肺部感染小鼠模型中,由克拉霉素、氯法齐明和贝达喹啉组成的治疗方案比单一疗法更有效。
bioRxiv. 2024 Dec 11:2024.12.11.627976. doi: 10.1101/2024.12.11.627976.

本文引用的文献

1
Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease.阿米卡星脂质体吸入混悬液治疗难治性鸟分枝杆菌复合群肺病的真实世界疗效
Tuberc Respir Dis (Seoul). 2024 Apr;87(2):202-205. doi: 10.4046/trd.2023.0120. Epub 2023 Sep 20.
2
The lung microbiota in nontuberculous mycobacterial pulmonary disease.非结核分枝杆菌肺病中的肺部微生物组。
PLoS One. 2023 May 26;18(5):e0285143. doi: 10.1371/journal.pone.0285143. eCollection 2023.
3
Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome.氯法齐明对非结核分枝杆菌临床分离株的最低抑菌浓度及其对治疗结局的影响。
Chest. 2021 Feb;159(2):517-523. doi: 10.1016/j.chest.2020.07.040. Epub 2020 Jul 24.
4
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.非结核分枝杆菌肺病的治疗:美国胸科学会/欧洲呼吸学会/欧洲临床微生物学与感染病学会/美国感染病学会官方临床实践指南
Eur Respir J. 2020 Jul 7;56(1). doi: 10.1183/13993003.00535-2020. Print 2020 Jul.
5
Clinical Characteristics and Outcomes of Surgically Resected Solitary Pulmonary Nodules Due to Nontuberculous Mycobacterial Infections.非结核分枝杆菌感染所致手术切除孤立性肺结节的临床特征及转归
J Clin Med. 2019 Nov 7;8(11):1898. doi: 10.3390/jcm8111898.
6
Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study.1445例非结核分枝杆菌肺病患者长期死亡率的预后因素:一项15年随访研究
Eur Respir J. 2020 Jan 2;55(1). doi: 10.1183/13993003.00798-2019. Print 2020 Jan.
7
Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease.非空洞性结节状支气管扩张性非结核分枝杆菌性肺病的长期自然病史。
Respir Med. 2019 May;151:1-7. doi: 10.1016/j.rmed.2019.03.014. Epub 2019 Mar 26.
8
The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease.非空洞性结节状支气管扩张分枝杆菌复合体肺病的自然病史。
Respir Med. 2019 Apr;150:45-50. doi: 10.1016/j.rmed.2019.02.007. Epub 2019 Feb 12.
9
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study.卷曲霉素脂质体吸入混悬液治疗复杂(CONVERT)引起的治疗抵抗性肺病。一项前瞻性、开放标签、随机研究。
Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
10
Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease.大环内酯类耐药与难治性鸟分枝杆菌复合群肺病再感染的发生
Am J Respir Crit Care Med. 2018 Nov 15;198(10):1322-1330. doi: 10.1164/rccm.201802-0321OC.

治疗失败的复杂肺部疾病患者的长期临床病程

Long-term clinical course of complex pulmonary disease patients with treatment failure.

作者信息

Zo Sungmin, Choe Junsu, Kim Dae Hun, Kim Su-Young, Jhun Byung Woo

机构信息

Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea.

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

出版信息

Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0105524. doi: 10.1128/aac.01055-24. Epub 2024 Oct 29.

DOI:10.1128/aac.01055-24
PMID:39470199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11619454/
Abstract

Despite guideline-based therapy, some patients with complex pulmonary disease (MAC-PD) experience treatment failure. We analyzed the clinical courses of 271 patients with treatment-refractory MAC-PD who discontinued therapy after at least 12 months. Patients were categorized into two groups-the retreatment group, who resumed antibiotics due to clinical or radiological deterioration, and the stable group, who did not require antibiotics. Of the study patients, 138 (51%) were in the retreatment group, whereas 133 (49%) were in the stable group. In the multivariate analysis models, an elevated erythrocyte sedimentation rate (adjusted hazard ratio [aHR] =1.01), the presence of a cavity (aHR = 1.75), and the number of lobes affected by bronchiectasis (aHR = 1.21) were associated with the need for retreatment. Our data indicated that approximately 50% of the patients with refractory MAC-PD who discontinued antibiotics eventually required retreatment, which was influenced by the extent of lung destruction or inflammation. These findings can aid in determining treatment strategies for patients with refractory diseases.

摘要

尽管采用了基于指南的治疗方法,但一些患有复杂性肺部疾病(MAC-PD)的患者仍经历治疗失败。我们分析了271例治疗难治性MAC-PD患者的临床病程,这些患者在至少12个月后停止治疗。患者被分为两组——再治疗组,因临床或影像学恶化而重新使用抗生素;稳定组,不需要使用抗生素。在研究患者中,138例(51%)在再治疗组,而133例(49%)在稳定组。在多变量分析模型中,红细胞沉降率升高(调整后风险比[aHR]=1.01)、存在空洞(aHR = 1.75)以及受支气管扩张影响的肺叶数量(aHR = 1.21)与再治疗需求相关。我们的数据表明,约50%停用抗生素的难治性MAC-PD患者最终需要再治疗,这受到肺破坏或炎症程度的影响。这些发现有助于为难治性疾病患者确定治疗策略。